Skip to main content
. 2021 Dec 30;19:1–11. doi: 10.1016/j.bioactmat.2021.12.018

Fig. 6.

Fig. 6

Anticancer efficacy of MOF-membrane-camouflaged nanoplatform against MCF-7/ADR tumours. PBS, MNP, free DOX, free PAB, PMNP, PMNP-DOX, and PMNP-DOX@RBC nanoparticles were intravenous injected on days 1, 3, and 5. a, Injection schedule. Tumour volume progression (b) and body weight change (e) within the 14-day observation period (n = 5). Images of tumour weight (c) and excised tumours (d) on day 14 (n = 5). *P < 0.05, **P < 0.01, ***P < 0.001. H&E-stained and GPX4-stained (f) tumour tissues harvested on the 14th day.